EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Kontrollierte klinische StudieMultizentrische Studie

A Phase I/II Trial of Sapanisertib in Advanced Anaplastic and Radioiodine Refractory Differentiated Thyroid Carcinoma

Kartik Sehgal iD, Anthony Serritella, Mofei Liu, Anne ONeill, Chaitali Nangia, Theodora Pappa, Michael J Demeure, Francis P Worden, Robert I Haddad, Jochen Lorch iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgae443 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Kartik Sehgal und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Division of Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Pyrimidines, Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Millennium Pharmaceuticals, Inc. (Cambridge, Takeda Pharmaceutical Company, Limited, Calithera Biosciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There are limited therapeutic options for patients with recurrent/metastatic anaplastic thyroid carcinoma (ATC) and radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC) refractory to multikinase inhibitors. This multicenter trial evaluated sapanisertib, a next-generation oral kinase inhibitor of mTOR complexes 1/2, in ATC and RAIR DTC.

Methods

A safety run-in phase I was followed by nonrandomized phase II trial in ATC, with an exploratory cohort in RAIR DTC. The primary endpoint was the proportion of patients with ATC who were without disease progression at 4 months. Safety and survival outcomes were key secondary endpoints.

Results

Forty-six patients (20 ATC, 26 DTC) were enrolled including 40 (18 ATC, 22 DTC) who received recommended phase II dose of 5 mg daily. Eleven percent [2/18, 95% confidence interval (CI): 1.4-34.7%] of patients with ATC were progression-free at 4 months; 22.2% (4/18) had stable disease as best response. Enrollment in the ATC cohort stopped early with 18 patients out of the proposed 23 due to overall futility. One confirmed partial response (4.5%, 1/22) occurred in RAIR DTC, with stable disease in 63.6% (14/22) patients. Median progression-free survival was 1.6 (95% CI: 0.9-2.8) months and 7.8 (2.0–not reached) months in ATC and DTC, respectively. Grade 3 treatment-related adverse events occurred in 30% of patients who received the phase II dose, with the most common being anorexia, nausea, diarrhea, fatigue, skin rash, and hyperglycemia. Genomic alterations in the PI3K/AKT/mTOR pathway were not associated with response or progression-free survival.

Conclusion

Sapanisertib monotherapy did not meet the primary endpoint of this trial (proportion progression-free at 4 months) in ATC and did not show clinically meaningful activity. Clinical trials with alternative therapeutic strategies are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsPyrimidinesThyroid Carcinoma, AnaplasticThyroid NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedIodine RadioisotopesAzepines

Stichwörter der Autor:innen

anaplastic thyroid carcinomamTORC1/2 inhibitorradioiodine refractory thyroid cancersapanisertib

Substanzen

Iodine RadioisotopesMLN 8237Protein Kinase InhibitorsPyrimidinesAzepines

Autor:innen und Institutionen

  • Department of Medical Oncology, Division of Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Harvard Medical School, Boston, MA 02115, USA.
  • Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
  • Thyroid Cancer Center, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Head and Neck/Thyroid Program, Robert H. Lurie Cancer Center of Northwestern University, Chicago, IL 60611, USA.
  • Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02116, USA.

ORCID-Profile: Kartik Sehgal, Jochen Lorch

Förderung

  • Millennium Pharmaceuticals, Inc. (Cambridge
  • Takeda Pharmaceutical Company, Limited
  • Calithera Biosciences

Zitieren

APA

Sehgal, K., Serritella, A., Liu, M., ONeill, A., Nangia, C., Pappa, T., Demeure, M. J., Worden, F. P., Haddad, R. I., & Lorch, J. (2025). A Phase I/II Trial of Sapanisertib in Advanced Anaplastic and Radioiodine Refractory Differentiated Thyroid Carcinoma. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae443

Vancouver

Sehgal K, Serritella A, Liu M, ONeill A, Nangia C, Pappa T, et al. A Phase I/II Trial of Sapanisertib in Advanced Anaplastic and Radioiodine Refractory Differentiated Thyroid Carcinoma. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae443

BibTeX
@article{Sehgal2025,
  author = {Sehgal, Kartik and Serritella, Anthony and Liu, Mofei and ONeill, Anne and Nangia, Chaitali and Pappa, Theodora and Demeure, Michael J and Worden, Francis P and Haddad, Robert I and Lorch, Jochen},
  title = {A Phase I/II Trial of Sapanisertib in Advanced Anaplastic and Radioiodine Refractory Differentiated Thyroid Carcinoma},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgae443}
}
Kostenlos starten →